Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.

Trial Details

NCT ID
NCT04776525
Phase
PHASE2
Sponsor
Oslo University Hospital
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Ifosfamide
  • Doxorubicin
Locations (sample)
  • Bergen, Norway|60.39299,5.32415
  • Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

  • ≥ 18 years of age at the time of informed consent.
  • Histological diagnosis of soft tissue sarcoma belonging to one of the following histotypes:
  • Leiomyosarcoma
  • Malignant peripheral nerve sheath tumor

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →